In the ever-evolving landscape of clinical trials, the importance of a carefully planned clinical outcome assessment (COA) strategy cannot be overstated. Navigating the complexities of data collection and patient engagement, it's crucial to make informed decisions that ensure the accuracy, reliability, and relevance of all assessments conducted within the clinical trial. At ICON, we understand the nuances involved in creating a COA strategy that not only meets regulatory standards but also resonates with patients and stakeholders alike.
Paper or electronic COAs: Making the right choice
One of the first decisions in developing a COA strategy is choosing between paper and electronic formats. While paper COAs have been a staple for decades, the rise of digital technology offers compelling advantages. Electronic COAs (eCOAs) enhance data accuracy, reduce entry errors, and improve patient compliance through ease of use and real-time data capture. However, the choice should be tailored to the specific needs of the trial, considering factors such as patient demographics, trial location, and the complexity of the assessment.
Incorporating wearable biometrics
In today's digital age, the integration of digital health technologies (DHTs), also known as biometric monitoring devices (BMD), such as smartwatches, chest straps, smart patches and monitors is a game-changer. Providing continuous, objective data that complements the COAs, researchers are provided a comprehensive view of patient health. Deciding whether to incorporate these technologies involves evaluating the specific outcomes being measured and the potential benefits of real-time biometric data.
Anticipating regulatory queries
Regulatory compliance is a critical concern in any clinical trial, and anticipating potential regulatory queries is key to a smooth approval process. A well-constructed COA strategy should include foresight into what data regulatory bodies might scrutinise. This involves understanding the specific requirements of different regulatory agencies and ensuring that the data collected is robust, comprehensive, and aligned with those expectations. By proactively addressing these concerns, the risk of regulatory delays can be minimised, and the path to approval can be more streamlined.
Seeking expert guidance for a comprehensive COA plan
Creating a successful COA strategy is a complex task that requires specialised knowledge and experience. Whether it's deciding on the right combination of traditional and digital assessments, determining the best use of wearable technology, or ensuring regulatory compliance, expert guidance is invaluable.
A unified approach under one roof
At ICON, we bring together all the elements of a COA strategy under one roof, providing a seamless and cohesive approach to clinical trial execution. Our integrated services ensure that every aspect of your COA strategy is meticulously planned and executed, reducing the complexity and ensuring consistency across the trial.
One of the key tools is Cassandra, which allows us to visualise potential regulatory queries before they arise. By leveraging this functionality, we can identify critical data points that need to be captured and ensure they are included in your COA strategy from the outset. This proactive approach helps mitigate risks and ensures that your trial is prepared for regulatory scrutiny.
ICON’s patient centred outcomes expertise spans four decades of innovation and research on directly engaging with patients across the entire healthcare landscape and through the entire treatment lifecycle. The Patient Centred Outcomes team are experts in the selection, design, development, and validation of clinical outcome assessments (COAs) and refinement of endpoint selections, preparation of COA dossiers for regulatory submissions; cognitive debriefing & usability testing (CDUT) and analysis of data for equivalent testing of COAs migrated to electronic platforms.
In partnership with Mapi Research Trust, ICON can source the most appropriate COAs for your trial, ensuring that they are scientifically validated and culturally relevant. This partnership also helps streamline the licensing process, so you can be confident that all necessary permissions are in place.
Translation and cognitive debriefing are critical services we provide. Accurate translation ensures that COAs are culturally and linguistically adapted for different target markets, maintaining the integrity and reliability of the data collected. Cognitive debriefing, meanwhile, validates that patients understand the COA instruments as intended, which is essential for capturing meaningful and accurate data.
ICON Outcome Measures offers a full-service approach to support sponsors in the identification, selection, and implementation of measures that matter to patients, from phase 1 through regulatory approval. Our Atlas system helps identify the right wearable biometric device into your trial. This technology allows for a patient-centric approach, ensuring that the wearables selected are not only relevant to the outcomes being measured but also user-friendly and compatible with patients' lifestyles.
Additionally, ICON’s capability to create eCOAs ensures that electronic assessments are not only accurate but also optimised for patient engagement. This includes designing interfaces that are intuitive and accessible, thereby enhancing patient compliance and data accuracy.
Delivering expertise as a collaborative, cohesive whole
Not only is ICON able to deliver all of these services to support the success of your clinical strategy, we can deliver this expertise to you as a collaborative and cohesive unit. From initial planning and regulatory foresight to COA selection, translation, cognitive debriefing, and the integration of wearable technology, we provide a comprehensive solution that covers every aspect of your clinical trial.
By partnering with ICON, sponsors can be assured that they are not just receiving individual services, but a fully integrated strategy that leverages our collective expertise to deliver a successful trial outcome. This unified approach under one roof ensures that your COA strategy is robust, compliant, and tailored to the unique needs of your clinical trial.
Contact our team of COA experts to learn more about how we can support your COA strategy.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel